-
公开(公告)号:EP2368890A1
公开(公告)日:2011-09-28
申请号:EP11160830.3
申请日:2010-06-10
Applicant: Abbott Laboratories
Inventor: Randolph, John T. , Degoey, David A. , Kati, Warren M. , Hutchins, Charles W. , Donner, Pamela L. , Krueger, Allan C. , Motter, Christopher E. , Nelson, Lissa T. , Patel, Sachin V. , Matulenko, Mark A. , Keddy, Ryan G. , Jinkerson, Tammie K. , Soltwedel, Todd N. , Hutchinson, Douglas K. , Flentge, Charles A. , Wagner, Charles A. , Maring, Clarence J. , Tufano, Michael D. , Betebenner, David A. , Rockway, Todd W. , Liu, Dachun , Pratt, John K. , Lavin, Michael J. , Sarris, Kathy , Woller, Kevin R. , Wagaw, Seble H. , Califano, Jean C. , Li, Wenke , Caspi, Daniel D. , Bellizzi, Mary E.
IPC: C07D403/14 , C07D401/14 , C07D417/14 , A61K31/4025 , A61K31/4178 , A61K31/4184 , A61K31/4196 , A61K31/4439 , A61P31/14
CPC classification number: C07F9/65583 , C07C33/26 , C07C201/06 , C07C205/19 , C07D207/08 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D471/04 , C07D491/113 , C07K5/06
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Abstract translation: 描述了有效抑制丙型肝炎病毒(“HCV”)复制的化合物。 本发明还涉及制备这种化合物的方法,包含这些化合物的组合物,以及使用这些化合物治疗HCV感染的方法。
-
2.Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) 有权
Title translation: Heterozyklische Verbindungen als丙型肝炎病毒(HCV)抑制剂公开(公告)号:EP2455376A1
公开(公告)日:2012-05-23
申请号:EP12155991.8
申请日:2010-06-10
Applicant: Abbott Laboratories
Inventor: Randolph, John T. , Matulenko, Mark A. , Keddy, Ryan G. , Jinkerson, Tammie K. , Hutchinson, Douglas K. , Flentge, Charles A. , Wagner, Rolf , Maring, Clarence J. , Tufano, Michael D. , Betebenner, David A. , Rockway, Todd W. , Degoey, David A. , Liu, Dachun , Pratt, John K. , Sarris, Kathy , Woller, Kevin R. , Wagaw, Seble H. , Califano, Jean C. , Li, Wenke , Caspi, Daniel D. , Bellizzi, Mary, E. , Gao, Yi , Kati, Warren M. , Hutchins, Charles W. , Donner, Pamela L. , Krueger, Allan C. , Motter, Christopher E , Nelson, Lissa T. , Patel, Sachin V.
IPC: C07D403/14 , C07D401/14 , C07D417/14 , A61K31/4025 , A61K31/4178 , A61K31/4184 , A61K31/4196 , A61K31/4439 , A61P31/14
CPC classification number: C07F9/65583 , C07C33/26 , C07C201/06 , C07C205/19 , C07D207/08 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D471/04 , C07D491/113 , C07K5/06
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Abstract translation: 描述了有效抑制丙型肝炎病毒(“HCV”)复制的化合物。 本发明还涉及制备这种化合物的方法,包含这些化合物的组合物,以及使用这些化合物治疗HCV感染的方法。
-
3.Tetrapeptide type-B CCK receptor ligands 失效
Title translation: Tetrapeptid-TYP-B-CCK-Rezeptor-Liganden。公开(公告)号:EP0405506A1
公开(公告)日:1991-01-02
申请号:EP90112261.4
申请日:1990-06-27
Applicant: ABBOTT LABORATORIES
Inventor: Chung, John Y.-L. , Tufano, Michael D. , May, Paul D. , Shiosaki, Kazumi , Nadzan, Alex M. , Garvey, David S. , Shue, Youe-Kong , Brodie, Mark S. , Holladay, Mark W.
CPC classification number: C07K5/1016 , A61K38/00 , C07K5/0207 , C07K5/0808 , C07K5/1024
Abstract: A tetrapeptide type-B CCK receptor ligand of the formula
A-B-C-D
or a pharmaceutically acceptable salt thereof, which is useful for treating central nervous system disorders, substance abuse, gastrointestinal disorders, endocrine disorders, eating-related disorders and treatment of shock, respiratory and cardiocirculatory insufficiencies.Abstract translation: 用于治疗中枢神经系统疾病,药物滥用,胃肠道疾病,内分泌紊乱,进食相关疾病和休克,呼吸和心脏循环治疗的ABCD的四肽B型CCK受体配体或其药学上可接受的盐 不足。
-
-